CING Cingulate Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1862150 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-240.8%
ROA-151.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.2%
Debt / equity0.00x
Current ratio3.90x
Interest coverage-25.09x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.91M | $1.49M | $2.18M | $2.00M | $2.85M | $2.70M | $2.22M | $4.33M |
| SG&A expense | $4.58M | $3.93M | $5.74M | $3.58M | $3.15M | $1.95M | $1.48M | $1.88M |
| Operating income | -$7.49M | -$5.41M | -$7.92M | -$5.59M | -$6.00M | -$4.65M | -$3.71M | -$6.21M |
| Interest expense | $184,659 | $236,375 | $348,315 | $283,499 | $194,444 | $213,711 | $209,671 | — |
| Pretax income | -$7.73M | -$5.87M | -$9.31M | -$6.27M | -$7.34M | -$4.98M | -$3.85M | -$6.23M |
| Net income | -$7.73M | -$5.87M | -$9.31M | -$6.27M | -$7.34M | -$4.98M | -$3.85M | -$6.23M |
| EBITDA | -$7.44M | -$5.32M | -$7.80M | -$5.46M | -$5.89M | -$4.50M | -$3.54M | -$6.05M |
| EPS (basic) | -0.53 | -0.45 | -0.95 | — | -1.35 | -1.14 | -1.06 | — |
| EPS (diluted) | -0.53 | -0.45 | -0.95 | — | -1.35 | -1.14 | -1.06 | — |
| Weighted avg. shares (diluted) | 14.55M | 13.19M | 9.78M | — | 5.43M | 4.39M | 3.65M | — |
| Banking | ||||||||
| Net interest income | -$171,056 | -$138,513 | -$528,267 | -$555,188 | -$572,228 | -$136,930 | -$96,784 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $23.19M | $28.40M | $25.89M | $10.95M | $6.12M | $8.90M | $9.52M | $12.21M |
| Current assets | $25.32M | $30.21M | $27.91M | $12.01M | $7.43M | $10.22M | $10.50M | $12.66M |
| PP&E, net | $1.67M | $1.63M | $1.67M | $1.73M | $1.69M | $1.80M | $1.94M | $2.10M |
| Total assets | $28.15M | $33.07M | $30.86M | $15.07M | $10.52M | $13.47M | $12.47M | $14.86M |
| Current liabilities | $6.48M | $8.63M | $10.96M | $10.31M | $5.88M | $6.73M | $5.62M | $4.97M |
| Total liabilities | $7.38M | $9.60M | $12.00M | $12.56M | $7.05M | $7.96M | $6.54M | $7.41M |
| Shareholders' equity | $20.77M | $23.47M | $18.86M | $2.51M | $3.47M | $5.51M | $5.93M | $7.46M |
| Shares outstanding | 14.76M | 13.89M | 11.91M | 7.25M | 5.98M | 4.89M | 3.83M | 3.40M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.38M | -$5.90M | -$6.91M | -$3.60M | -$4.24M | -$4.80M | -$4.61M | -$4.08M |
| Capital expenditure | $83,183 | $67,080 | $61,183 | $156,213 | $0 | — | — | $198,462 |
| Free cash flow | -$7.47M | -$5.97M | -$6.97M | -$3.75M | -$4.24M | — | — | -$4.28M |
| Investing cash flow | -$83,183 | -$67,080 | -$61,183 | -$156,213 | $0 | — | — | -$198,462 |
| Financing cash flow | $2.25M | $8.48M | $21.91M | $8.59M | $1.46M | $4.18M | $1.92M | $6.45M |
| Depreciation & amortization | $46,718 | $98,243 | $121,185 | $121,832 | $106,782 | $146,989 | $165,291 | $160,302 |
| Stock-based compensation | $733,285 | $362,227 | $593,100 | $385,965 | $592,824 | $187,390 | $357,649 | $60,349 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.